Several cancer-targeted drugs have been developed, including gefitinib for non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) expression, crizotinib for NSCLC with ALK mutations, sorafenib targeting VEGFR in various types of cancers, bevacizumab for metastatic colorectal cancer, and trastuzumab for breast cancer with HER-2 overexpression68. Here, ALK is linked to non-small cell lung carcinoma.